After Cowen & Co. and William Blair gave Albireo Pharma Inc (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos maintained a Buy rating on Albireo Pharma Inc today and set a price target of $69. The company’s shares closed yesterday at $24.75.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.9% and a 28.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma Inc with a $60.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.69 and a one-year low of $19.10. Currently, Albireo Pharma Inc has an average volume of 67.51K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.
